NeoGenomics reported a 10% growth in second-quarter 2025 revenues to $181.3 million, but results fell short of analyst expectations. The company lowered its full-year revenue and earnings projections citing weaker-than-expected biopharmaceutical service contributions and delays in launching the PanTracer liquid biopsy test. The shares dropped nearly 20% following the guidance cut, reflecting investor concerns over the company’s competitive positioning against better-funded rivals in next-generation sequencing and liquid biopsy markets. NeoGenomics is responding by boosting R&D and sales efforts to revitalize its oncology and molecular diagnostic offerings.